CRISPR Therapeutics
CRSP
CRSP
495 hedge funds and large institutions have $6.57B invested in CRISPR Therapeutics in 2021 Q2 according to their latest regulatory filings, with 110 funds opening new positions, 171 increasing their positions, 125 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
495
Holders Change
+54
Holders Change %
+12.24%
% of All Funds
8.64%
Holding in Top 10
12
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+140%
% of All Funds
0.21%
New
110
Increased
171
Reduced
125
Closed
53
Calls
$509M
Puts
$570M
Net Calls
-$61.2M
Net Calls Change
-$25.4M
Top Buyers
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$187M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$147M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$34.2M |
| 4 |
DVF
Discovery Value Fund
Singapore
|
+$30.1M |
| 5 |
HCS
Himension Capital (Singapore)
Singapore
|
+$25.5M |
